Literature DB >> 19857741

Vitamin D metabolite-mediated hypercalcemia with suppressed parathormone concentration in Pneumocystis jiroveci pneumonia after kidney transplantation.

K Hajji1, F Dalle, A Harzallah, Y Tanter, G Rifle, C Mousson.   

Abstract

Pneumocystis jiroveci pneumonia (PJP) is a severe complication in immunocompromised hosts including transplant recipients. Hypercalcemia (HCa) is not a classic symptom of the disease. However, HCa (mean [SD; range], 2.90 [0.20; 2.71-3.17] mmol/L) was detected in 5 patients with PJP at diagnosis. The HCa was associated with decreased concentrations of circulating parathormone (PTH), from 294 (292) ng/L 3 to 6 months previously to 20 (23.5; 7-53) ng/L. Concentrations of 1,25-(OH)2 vitamin D, measured in 3 patients, were in the high normal range (54.66 [7.23; 225-66] microg/L), whereas 25-(OH) vitamin D concentrations were low (13.9 [2.17; 20-60] microg/L). After treatment with trimethoprim-sulfamethoxazole for 21 days, 4 patients recovered and 1 died. Calcium and PTH concentrations rapidly returned to normal (2.36 [0.05] mmol/L and 89 [29.7] ng/L, respectively) at 2 months after the acute phase of the disease. Although fewer than 10 cases of PJP-associated HCa have been reported to date, it is possible that this association is more frequent than previously thought because our cases were detected during 2 years. As in other granulomatous disease-induced HCa, including fungal infections, it is likely that endogenous extrarenal production of 1-alpha-hydroxylase by activated macrophages and by interferon-gamma involved in granuloma formation results in increased conversion from 25-(OH) vitamin D to 1,25-(OH)2 vitamin D and, consequently, in transient HCa and suppression of PTH secretion. Fortuitous detection of HCa in transplant recipients with pulmonary symptoms must raise suspicion of PJP or fungal infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857741     DOI: 10.1016/j.transproceed.2009.08.037

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

Review 1.  Hypercalcemia: a consultant's approach.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2017-09-06       Impact factor: 3.714

2.  Hypercalcemia Heralding Pneumocystis jirovecii Pneumonia in an HIV-Seronegative Patient with Diffuse Cutaneous Systemic Sclerosis.

Authors:  Quentin Binet; Jacques Mairesse; Marie Vanthuyne; Jean-Christophe Marot; Grégoire Wieers
Journal:  Mycopathologia       Date:  2019-11-15       Impact factor: 2.574

3.  Hypercalcaemia preceding diagnosis of Pneumocystis jirovecii pneumonia in renal transplant recipients.

Authors:  Jonathan Ling; Tara Anderson; Sanchia Warren; Geoffrey Kirkland; Matthew Jose; Richard Yu; Steven Yew; Samantha Mcfadyen; Alison Graver; William Johnson; Lisa Jeffs
Journal:  Clin Kidney J       Date:  2017-06-23

4.  Severe hypercalcemia preceding a diagnosis of Pneumocystis jirovecii pneumonia in a liver transplant recipient.

Authors:  Amy A Yau; Samira S Farouk
Journal:  BMC Infect Dis       Date:  2019-08-22       Impact factor: 3.090

5.  Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients.

Authors:  Aghilès Hamroun; Rémi Lenain; Linh Bui Nguyen; Paul Chamley; Séverine Loridant; Yann Neugebauer; Arnaud Lionet; Marie Frimat; Marc Hazzan
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

6.  Life-Threatening Hypercalcemia During Prodrome of Pneumocystis jiroveci Pneumonia in an Immunocompetent Infant.

Authors:  Judith Sebestyen VanSickle; Tarak Srivastava; Uri S Alon
Journal:  Glob Pediatr Health       Date:  2017-05-02

7.  Distinct Clinical and Laboratory Patterns of Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients.

Authors:  Andreas M J Meyer; Daniel Sidler; Cédric Hirzel; Hansjakob Furrer; Lukas Ebner; Alan A Peters; Andreas Christe; Uyen Huynh-Do; Laura N Walti; Spyridon Arampatzis
Journal:  J Fungi (Basel)       Date:  2021-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.